Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Parameter
Parameter
Diversity in testing for platelet function disorders by light transmission aggregometry in the Netherlands
Laboratory Tests
Activated Clotting Time (ACT)
Activated Partial Thromboplastin Time (APTT)
Activated Protein C resistance (APC-R)
ADAMTS13 activity, antigen and inhibitor
Anti-Xa (Clotting-based and Chromogenic)
Anticardiolipin (aCL) and Anti-β2-Glycoprotein I (Anti-β2GPI)
Antithrombin (Chromogenic and Immunological)
Ecarin Clotting Time
Factor Assays APTT-Based (1-Stage)
Factor Assays PT-Based (1-Stage)
Factor IX (Chromogenic)
Factor V Leiden (F5 Arg506Gln)
Factor VIII (Clotting-based and Chromogenic)
Factor VIII Binding (VWF:FVIIIB)
Factor VIII inhibitor
Factor X Assay (RVV)
Factor XIII
Fibrinogen
Fibrinolysis: D-Dimer
Fibrinolysis: Euglobulin Clot Lysis Time (ECLT)
Fibrinolysis: Fibrinogen Degradation Products (FDP)
Fibrinolysis: Global Fibrinolytic Capacity (GFC) and Clot Formation and Lysis (CloFAL)
Fibrinolysis: Plasminogen (Plg)
Fibrinolysis: Plasminogen Activator Inhibitor Type 1 (PAI-1): Serpin E1
Fibrinolysis: Thrombin Activatable Fibrinolysis Inhibitor (TAFI)
Fibrinolysis: Tissue-type Plasminogen Activator (t-PA)
Fibrinolysis: Urokinase-type Plasminogen Activator (u-PA)
Fibrinolysis: Venous Occlusion Test
Fibrinolysis: α2-Plasmin Inhibitor
Global Thrombosis Test (GTT)
Heparin Cofactor II (HCII)
Heparin Induced Thrombocytopenia (HIT), Anti-Platelet Factor 4 (PF4)
Homocysteine (Hcy)
International Sensitivity Index (ISI) & The International Normalised Ratio (INR)
Lupus Anticoagulant (LA): Dilute Russell Viper Venom Time (dRVVT)
Lupus Anticoagulant (LA): Dilute Thromboplastin Inhibition (DTI)
Lupus Anticoagulant (LA): Kaolin Clotting Time (KCT)
Lupus Anticoagulant (LA): Silica Clotting Time (SCT)
Lupus Anticoagulant (LA): Taipan Venom Time
Lupus Anticoagulant (LA): Textarin:Ecarin Ratio and Taipan:Ecarin Ratio
Platelet Function: Flow Cytometry
Platelet Function: Impedance Platelet Aggregometry
Platelet Function: Light Transmission Aggregometry (LTA)
Platelet Function: PFA-100/200
Platelet Function: Platelet Nucleotides
Platelet Function: Platelet Procoagulant Activity (PCA)
Platelet Function: VerifyNow
Protamine Sulphate Neutralisation Test
Protein C (Clotting-based, Immunological and Chromogenic)
Protein C (ProC) Global Assay
Protein S (Clotting-based and Immunological)
Prothrombin (F2) G20210A Mutation
Prothrombin Fragment 1+2 (F1+2)
Prothrombin Time (PT)
Prothrombinase-induced Clotting Test (PiCT)
ReoRox G2
Reptilase (Batroxobin) Time
Ristocetin-Induced Platelet Agglutination (RIPA)
The Bleeding Time (BT)
Thrombin Generation (Clotting-based, Chromogenic and Fluorogenic)
Thrombin Time (TT)
Thromboelastography (TEG) & Rotational Thromboelastometry (ROTEM)
Von Willebrand Collagen Binding (VWF:CB)
Von Willebrand Factor (VWF) Inhibitor
Von Willebrand Factor (VWF) Multimers
Von Willebrand Factor Activity (VWF:Act)
Von Willebrand Factor antigeen (VWF:Ag)
Von Willebrand Factor Propeptide (VWFpp)
Von Willebrand Factor Ristocetin Cofactor (VWF:RCo)
Test Information
4Ts Score for the diagnosis of HIT
An introduction to haemophilia
Antibodies against factor XIII subunits
Antibodies to blood coagulation factors; immunological background
Assay systems to measure platelet-dependent von Willebrand factor activity (GPIbα binding)
Clinical features of inhibitors in haemophilia A
Current classification, diagnosis and treatment of von Willebrand disease
Development of platelet function testing guidelines
Direct oral anticoagulants in atrial fibrillation
Direct Oral AntiCoagulants in Venous Thromboembolism
Factor XIII in thrombotic diseases
Flowcytometry for evaluation of platelet disorders
Future approaches to studying platelet function
Genetics of Factor XIII
Guideline for the treatment and prevention of HIT. A summary of the CHEST ACCP Guideline 9th edition.
Heparin-Induced Thrombocytopenia. Is there an alternative for unfractionated heparin?
Heparin, a short overview
Influence of Direct Oral AntiCoagulants on coagulation assays and the factors to consider for correctly interpreting tests
Inherited and acquired platelet function disorders
Inherited FXIII deficiency: clinical symptoms
Inhibitors against ADAMTS13
Inhibitors in mild or moderate hemophilia A
Laboratory measurement of Direct Oral AntiCoagulants (DOACs)
Laboratory measurement of extended half-life FIX concentrates
Laboratory measurement of extended half-life FVIII products
Laboratory monitoring of new hemostatic agents (Long-acting factor concentrates)
Management of bleeding complications in patients treated with Direct Oral AntiCoagulants
Measurement of factor VIII for the diagnosis of haemophilia A
Measurement of Factor VIII inhibitors: Detection, Improvement and Perspectives
Molecular testing for platelet function disorders
Monitoring antiplatelet therapy
New developments in the treatment of haemophilia
New developments in the treatment of haemophilia: implications for laboratory testing
Optimizing prophylactic treatment in haemophilia: when to use longer-acting products
Pathophysiology of heparin-induced thrombocytopenia
Patient-tailored therapy in haemophilia A: Towards pharmacokinetically guided dosing of factor VIII replacement therapy
Personalising therapy in haemophilia Pharmacokinetic-guided dosing of factor VIII and factor IX concentrates
Phenotype and genotype associations in von Willebrand disease
Platelet aggregometry/lumi-aggregometry
Platelet Transmission Electron Microscopy
Platelets in inflammation, infection and cancer
Potency labelling of extended half-life FVIII and FIX products
Quality Control for the Platelet Function Analyser (PFA)
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
Role of gene therapy in the future treatment of haemophilia patients
The comparison between unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) for avoiding HIT
The detection of Factor VIII Inhibitors with the Nijmegen assay
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
The future of haemophilia treatment: beyond the suppletion of factor VIII and IX
The genetic background of haemophilia
The ideal AntiCoagulant Drug
The Laboratory Diagnosis of HIT
The laboratory diagnosis of inherited FXIII deficiencies and the measurement of FXIII activity and antigen level
The measurement of Direct Oral AntiCoagulants in urine by a point-of-care test
The multimer analysis
The organization of thrombosis care
The role of Factor XIII in fibrin clot formation
The role of the clinical laboratory in the management of patients treated with Direct Oral AntiCoagulants
Type 2N von Willebrand disease: clinical, therapeutical and laboratory aspects
Update on platelet aggregation testing
Validation of methods in hemostasis testing: a practical approach
Von Willebrand Disease Testing Repertoire:The Past, Present and Future
Wet Workshop on Platelet Function Testing
Questions or suggestions?
Clotpedia Support Form
Submit
Success